The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine.
dc.contributor.author | Doddakula, Kishore K | |
dc.contributor.author | Neary, Peter M | |
dc.contributor.author | Wang, Jiang H | |
dc.contributor.author | Sookhai, Shastri | |
dc.contributor.author | O'Donnell, Aongus | |
dc.contributor.author | Aherne, Tom | |
dc.contributor.author | Bouchier-Hayes, David J | |
dc.contributor.author | Redmond, Henry P | |
dc.date.accessioned | 2012-01-05T12:24:13Z | |
dc.date.available | 2012-01-05T12:24:13Z | |
dc.date.issued | 2010-09 | |
dc.identifier.citation | The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine. 2010, 148 (3):567-72 Surgery | en |
dc.identifier.issn | 1532-7361 | |
dc.identifier.pmid | 20223497 | |
dc.identifier.doi | 10.1016/j.surg.2010.01.006 | |
dc.identifier.uri | http://hdl.handle.net/10147/200243 | |
dc.description.abstract | Cardiopulmonary bypass results in ischemia/reperfusion (I/R)-induced endotoxemia. We conducted a prospective randomized trial to investigate the effect of taurolidine, an antiendotoxin agent with antioxidant and membrane-stabilizing properties, on patients undergoing coronary artery bypass grafting (CABG). | |
dc.description.abstract | A total of 60 patients undergoing CABG were randomized into 4 groups. St Thomas' Hospital cold crystalloid cardioplegia was used in groups A and B, and cold blood cardioplegia in groups C and D. Groups A and C received a placebo infusion of normal saline, whereas groups B and D were administered intravenous taurolidine. Arrhythmias induced by pro- and anti-inflammatory cytokines (interleukin [IL]-6 and IL-10), and I/R were assessed perioperatively. | |
dc.description.abstract | Administration of taurolidine in crystalloid cardioplegia patients resulted in a significant decrease in serum IL-6 and an increase in serum IL-10 at 24 hours postaortic unclamping compared to placebo (P < .0001). Although not statistically significant, this trend in serum IL-6 decrease was mirrored in the blood cardioplegia patients (P = .068). Taurolidine treatment also significantly decreased I/R-induced arrhythmias compared to placebo in the crystalloid cardioplegia patients (P < .003). There were fewer I/R-induced arrhythmias compared to placebo in the blood cardioplegia patients; the difference, however, was marginal and not statistically significant (P = .583). | |
dc.description.abstract | This study demonstrates that administration of taurolidine in CABG patients induces a potent anti-inflammatory response that is associated with a significant decrease in arrhythmias. | |
dc.language.iso | en | en |
dc.publisher | Mosby Inc. | en |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antioxidants | |
dc.subject.mesh | Cardiopulmonary Bypass | |
dc.subject.mesh | Constriction | |
dc.subject.mesh | Coronary Artery Bypass | |
dc.subject.mesh | Endotoxins | |
dc.subject.mesh | Female | |
dc.subject.mesh | Heart Arrest, Induced | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Interleukin-10 | |
dc.subject.mesh | Interleukin-6 | |
dc.subject.mesh | Length of Stay | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Phagocytosis | |
dc.subject.mesh | Placebos | |
dc.subject.mesh | Reperfusion Injury | |
dc.subject.mesh | Respiratory Burst | |
dc.subject.mesh | Taurine | |
dc.title | The antiendotoxin agent taurolidine potentially reduces ischemia/reperfusion injury through its metabolite taurine. | en |
dc.type | Article | en |
dc.contributor.department | Department of Cardiac Surgery, University College Cork, Cork University Hospital, Cork, Ireland. | en |
dc.identifier.journal | Surgery | en |
dc.description.province | Munster | |
html.description.abstract | Cardiopulmonary bypass results in ischemia/reperfusion (I/R)-induced endotoxemia. We conducted a prospective randomized trial to investigate the effect of taurolidine, an antiendotoxin agent with antioxidant and membrane-stabilizing properties, on patients undergoing coronary artery bypass grafting (CABG). | |
html.description.abstract | A total of 60 patients undergoing CABG were randomized into 4 groups. St Thomas' Hospital cold crystalloid cardioplegia was used in groups A and B, and cold blood cardioplegia in groups C and D. Groups A and C received a placebo infusion of normal saline, whereas groups B and D were administered intravenous taurolidine. Arrhythmias induced by pro- and anti-inflammatory cytokines (interleukin [IL]-6 and IL-10), and I/R were assessed perioperatively. | |
html.description.abstract | Administration of taurolidine in crystalloid cardioplegia patients resulted in a significant decrease in serum IL-6 and an increase in serum IL-10 at 24 hours postaortic unclamping compared to placebo (P < .0001). Although not statistically significant, this trend in serum IL-6 decrease was mirrored in the blood cardioplegia patients (P = .068). Taurolidine treatment also significantly decreased I/R-induced arrhythmias compared to placebo in the crystalloid cardioplegia patients (P < .003). There were fewer I/R-induced arrhythmias compared to placebo in the blood cardioplegia patients; the difference, however, was marginal and not statistically significant (P = .583). | |
html.description.abstract | This study demonstrates that administration of taurolidine in CABG patients induces a potent anti-inflammatory response that is associated with a significant decrease in arrhythmias. |